NYSE:PBH - Prestige Consumer Healthcare Stock Price, News, & Analysis

Prestige Consumer Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBH."

Prestige Consumer Healthcare Inc (NYSE:PBH) posted its quarterly earnings data on Thursday, February, 7th. The company reported $0.73 EPS for the quarter, beating the Zacks' consensus estimate of $0.71 by $0.02. The firm had revenue of $241.40 million for the quarter, compared to the consensus estimate of $241.40 million. Prestige Consumer Healthcare had a net margin of 6.44% and a return on equity of 11.85%. The firm's revenue was down 10.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.70 EPS. View Prestige Consumer Healthcare's Earnings History.

Prestige Consumer Healthcare is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for Prestige Consumer Healthcare.

Prestige Consumer Healthcare issued an update on its FY19 earnings guidance on Thursday, February, 7th. The company provided EPS guidance of $2.75-$2.78 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.76. The company issued revenue guidance of $970-$975 million, compared to the consensus revenue estimate of $971.99 million.Prestige Consumer Healthcare also updated its FY 2019 guidance to $2.75-2.78 EPS.

4 equities research analysts have issued 12-month target prices for Prestige Consumer Healthcare's shares. Their forecasts range from $28.40 to $88.00. On average, they anticipate Prestige Consumer Healthcare's share price to reach $48.10 in the next year. This suggests a possible upside of 68.7% from the stock's current price. View Analyst Price Targets for Prestige Consumer Healthcare.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prestige Consumer Healthcare in the last year. There are currently 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Prestige Consumer Healthcare.

Media headlines about PBH stock have been trending somewhat positive recently, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Prestige Consumer Healthcare earned a media sentiment score of 1.6 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next few days.

Some companies that are related to Prestige Consumer Healthcare include Amarin (AMRN), GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR), Patheon (PTHN), Alkermes (ALKS), Array Biopharma (ARRY), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), Taro Pharmaceutical Industries (TARO), TESARO (TSRO), Amneal Pharmaceuticals (AMRX), Horizon Pharma (HZNP), Agios Pharmaceuticals (AGIO), HUTCHISON CHINA/S (HCM) and Evotec (EVTCY).

Prestige Consumer Healthcare's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.48%), Dimensional Fund Advisors LP (7.82%), Macquarie Group Ltd. (2.79%), Fisher Asset Management LLC (2.41%), Acadian Asset Management LLC (2.39%) and Northern Trust Corp (1.65%). Company insiders that own Prestige Consumer Healthcare stock include Gary E Costley, Jean A Boyko, Natale S Ricciardi, Ronald M Lombardi, Timothy Connors and William P'pool. View Institutional Ownership Trends for Prestige Consumer Healthcare.

PBH stock was sold by a variety of institutional investors in the last quarter, including Standard Life Aberdeen plc, Bank of America Corp DE, Prudential Financial Inc., Nuveen Asset Management LLC, Fiera Capital Corp, Foresters Investment Management Company Inc., Barclays PLC and Principal Financial Group Inc.. Company insiders that have sold Prestige Consumer Healthcare company stock in the last year include Jean A Boyko and Timothy Connors. View Insider Buying and Selling for Prestige Consumer Healthcare.

PBH stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, LSV Asset Management, BlackRock Inc., Acadian Asset Management LLC, Macquarie Group Ltd., State of Tennessee Treasury Department, D. E. Shaw & Co. Inc. and Millennium Management LLC. Company insiders that have bought Prestige Consumer Healthcare stock in the last two years include Gary E Costley, Natale S Ricciardi, Ronald M Lombardi and William P'pool. View Insider Buying and Selling for Prestige Consumer Healthcare.

Shares of PBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PBH stock can currently be purchased for approximately $28.52.

Prestige Consumer Healthcare has a market capitalization of $1.48 billion and generates $1.04 billion in revenue each year. The company earns $339.57 million in net income (profit) each year or $2.58 on an earnings per share basis. Prestige Consumer Healthcare employs 530 workers across the globe.

The official website for Prestige Consumer Healthcare is http://www.prestigebrands.com.

Prestige Consumer Healthcare's mailing address is 660 WHITE PLAINS ROAD SUITE 250, TARRYTOWN NY, 10591. The company can be reached via phone at 914-524-6800 or via email at [email protected]